Praxis Precision Medicines shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $155 price target.
Portfolio Pulse from Benzinga Newsdesk
Praxis Precision Medicines shares are trading higher after Guggenheim initiated coverage with a Buy rating and a $155 price target.

June 18, 2024 | 1:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Praxis Precision Medicines shares are trading higher following Guggenheim's initiation of coverage with a Buy rating and a $155 price target.
The initiation of coverage by a major financial institution like Guggenheim with a Buy rating and a high price target is a strong positive signal for investors. This is likely to drive short-term buying interest and increase the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100